Literature DB >> 15336721

Embryotoxicity study of ginsenoside Rc and Re in in vitro rat whole embryo culture.

Louis Y Chan1, Pui Y Chiu, Tze K Lau.   

Abstract

BACKGROUND: Pregnant women commonly consume ginseng. However, there is little data concerning the effects of ginseng on early pregnancy.
METHODS: Rat embryos were exposed in vitro to different concentrations of Rc and Re from day 9.5 to day 11.5 after conception. Embryos were scored for growth and differentiation at the end of the culture period.
RESULTS: Embryos exposed to 50.0 microg/ml Re had significantly lower median morphological score (29.0 versus 48.0), fewer number of somites (15.0 versus 21.0), and smaller yolk sac diameter (3.5 versus 4.1 mm) and crown-rump length (CRL) (2.9 versus 3.4 mm) compare to control embryos. There was no significant difference between embryos exposed to 5.0 microg/ml Re and control embryos. There was also no difference in the biometric and morphologic parameters among control and embryos exposed to 5.0 and 50.0 microg/ml Rc.
CONCLUSION: There is a significant variability in embryotoxic effects of different ginsenosides. Further studies to evaluate the synergistic embryotoxic effects of ginsenosides are warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336721     DOI: 10.1016/j.reprotox.2004.06.001

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  10 in total

Review 1.  Therapeutic potential of ginseng in the management of cardiovascular disorders.

Authors:  Morris Karmazyn; Melissa Moey; Xiaohong Tracey Gan
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

2.  Rg3 and Rh2 ginsenosides suppress embryoid body formation by inhibiting the epithelial-mesenchymal transition.

Authors:  Jae Sung Noh; Jae Kyun Jeong; Jeung-Whan Han; Sang Ah Yi
Journal:  Arch Pharm Res       Date:  2022-06-27       Impact factor: 6.010

Review 3.  Ginseng compounds: an update on their molecular mechanisms and medical applications.

Authors:  Jian-Ming Lü; Qizhi Yao; Changyi Chen
Journal:  Curr Vasc Pharmacol       Date:  2009-07       Impact factor: 2.719

Review 4.  Review of cases of patient risk associated with ginseng abuse and misuse.

Authors:  Doo Jin Paik; Chang Ho Lee
Journal:  J Ginseng Res       Date:  2014-12-06       Impact factor: 6.060

Review 5.  Use of lipid-lowering medicinal herbs during pregnancy: A systematic review on safety and dosage.

Authors:  Hojjat Rouhi-Boroujeni; Esfandiar Heidarian; Hamid Rouhi-Boroujeni; Minasadat Khoddami; Mojgan Gharipour; Mahmoud Rafieian-Kopaei
Journal:  ARYA Atheroscler       Date:  2017-05

6.  Developmental and reproductive toxicity assessment in rats with KGC-HJ3, Korean Red Ginseng with Angelica gigas and Deer antlers.

Authors:  Jinsoo Lee; Ji-Seong Jeong; Kyung-Jin Cho; Kyeong-Nang Moon; Sang Yun Kim; Byungcheol Han; Yong-Soon Kim; Eun Ju Jeong; Moon-Koo Chung; Wook-Joon Yu
Journal:  J Ginseng Res       Date:  2018-01-10       Impact factor: 6.060

Review 7.  Panax ginseng and Panax quinquefolius: From pharmacology to toxicology.

Authors:  Cesare Mancuso; Rosaria Santangelo
Journal:  Food Chem Toxicol       Date:  2017-07-08       Impact factor: 6.023

Review 8.  Toxicity as prime selection criterion among SARS-active herbal medications.

Authors:  Franz Oesch; Barbara Oesch-Bartlomowicz; Thomas Efferth
Journal:  Phytomedicine       Date:  2021-01-28       Impact factor: 5.340

Review 9.  Inhibition of Myocardial Cell Apoptosis Is Important Mechanism for Ginsenoside in the Limitation of Myocardial Ischemia/Reperfusion Injury.

Authors:  Zhihan Chen; Jingping Wu; Sijing Li; Caijiao Liu; Yulan Ren
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 10.  Pharmacological Properties of Ginsenoside Re.

Authors:  Xiao-Yan Gao; Guan-Cheng Liu; Jian-Xiu Zhang; Ling-He Wang; Chang Xu; Zi-An Yan; Ao Wang; Yi-Fei Su; Jung-Joon Lee; Guang-Chun Piao; Hai-Dan Yuan
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.